Screener
AngioDynamics ANGO Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The source filing: AngioDynamics’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 3:42 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-048138
| Line item | Year ended May 31, 2026 | Year ended May 31, 2025 | Year ended May 31, 2024 |
|---|---|---|---|
| Transaction costs for disposition | — | — | (5,084) |
| Change in fair value of contingent consideration | — | 272 | 432 |
| Deferred income tax provision | 143 | (988) | (7,968) |
| Changes in accounts receivable allowances | 313 | 699 | 1,326 |
| Asset impairments and disposals | 1,304 | 173 | 7,108 |
| Write-off of other assets | — | — | 869 |
| Other | 1,969 | 291 | (62) |
| Changes in operating assets and liabilities: |
Item 15. Exhibits, Financial Statement Schedules.
FAQ
- What is AngioDynamics's accounts receivable, credit loss expense (reversal)?
- AngioDynamics (ANGO) reported accounts receivable, credit loss expense (reversal) of $123K in Q1 2026.
- How has AngioDynamics's accounts receivable, credit loss expense (reversal) changed year-over-year?
- AngioDynamics's accounts receivable, credit loss expense (reversal) decreased by 27.2% year-over-year, from $169K to $123K.
- What is the long-term trend for AngioDynamics's accounts receivable, credit loss expense (reversal)?
- Over 4 years (2022 to 2026), AngioDynamics's accounts receivable, credit loss expense (reversal) has grown at a 27.6% compound annual growth rate (CAGR), from $118K to $313K.
Ask your AI about AngioDynamics's accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude